BD is committed to providing patients with safe and effective products, and we stand by the performance and integrity of every product we manufacture, including all pen needles and safety pen needles, which have a long history of customer satisfaction. Therefore, we are taking prompt action due to the Safety Communication entitled “Caution When Using Pen Needles to Inject Medicines: FDA Safety Communication” released by the United States Food and Drug Administration on September 27, 2018. While BD Diabetes Care has not been made aware of any concerns with BD product specifically, BD will continue to evaluate this Safety Communication, engage with FDA on next steps and will take any action as appropriate. Please see linked IFU for reference.
